GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'

GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a preclinical 30-plus valent shot. A spokesperson for GSK said “increased competition” drove the decision.